Last reviewed · How we verify
NCT03139747
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Phase 2 trial testing Lenvatinib in Thyroid Cancer in 5 participants. Suspended.
30 May 2022
Quick facts
| Lead sponsor | Thomas Jefferson University |
|---|---|
| Phase | Phase 2 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 3 April 2017 |
| Primary completion | 30 May 2022 |
| Estimated completion | 30 May 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Lenvatinib (LENVATINIB) — full drug profile →
- Everolimus (everolimus) — full drug profile →
Conditions studied
- Thyroid Cancer — all drugs for Thyroid Cancer →
Sponsor
Thomas Jefferson University
Who can join
18 and older, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 2 Study of Everolimus and Lenvatinib in patients with metastatic differentiated thyroid cancer who have progressed on lenvatinib alone. Patient will have imaging, lab test and physical exams
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Updates on the Management of Thyroid Cancer.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. · · 2020 · cited 115× · PMID 32040962 · DOI 10.1055/a-1089-7870 -
New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071 -
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E, Martorana F, Romano C, Vitale SR, et al · · 2019 · cited 63× · PMID 31540307 · DOI 10.3390/genes10090709 -
Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.
Manzella L, Massimino M, Stella S, Tirrò E, et al · · 2019 · cited 43× · PMID 31269742 · DOI 10.3390/ijms20133258 -
Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.
San Román Gil M, Pozas J, Molina-Cerrillo J, Gómez J, et al · · 2020 · cited 11× · PMID 32668761 · DOI 10.3390/ijms21144951 -
Kinase inhibitors in thyroid cancers.
Sukrithan V, Jain P, Shah MH, Konda B. · · 2023 · cited 7× · PMID 37434642 · DOI 10.1530/eo-22-0062 -
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
Su JY, Huang T, Zhang JL, Lu JH, et al · · 2024 · cited 1× · PMID 38455407 · DOI 10.62347/ejaa3388
Verify or expand the search:
- PubMed search for NCT03139747
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lenvatinib
Trials testing the same drug.
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
- NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
- NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting
Other recruiting trials for Thyroid Cancer
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other Thomas Jefferson University trials
Trials by the same sponsor.
- NCT07526480 — Improving Dementia Care in Primary Practice · NA · not yet recruiting
- NCT07414550 — Radiotherapy for Refractory Hidradenitis Suppurativa · NA · not yet recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07217197 — Respiratory Monitoring System That Detects & Predicts OIRD · NA · enrolling by invitation
- NCT07145099 — The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03139747 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thomas Jefferson University
- Last refreshed: 15 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03139747.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing